DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Vuky J, Vasant Balar A, Castellano DE. et al.
Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
Journal of Clinical Oncol 2018;
36 (Suppl. 15) 4524-4524
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.